European product
CE marking
MDR certification
Backed by clinical trials
Private label available
TrHCROSS 2.0 %
Intra-articular injection of cross-linked hyaluronic acid.
Formulated using SARE Technology to ensure improved joint function and longer-lasting results.
- Concentration
- 20 mg/mL
- Presentation
- 4.4 mL disposable, non-pyrogenic, sterile prefilled syringe with Luer lock
- Certification
- Class III Medical Device (MDR)
- Recommended needle
- 19G
- Shelf life
- 2 years
- Technology
- SARE Technology (HA Crosslinking Tech)
- Presentation
- 4.4 mL disposable, non-pyrogenic, sterile prefilled syringe with Luer lock
SARE Technology
Reducción del dolor
Efecto duradero
Propiedades viscoelásticas
Viscosuplementación
Advantages
- Manufactured in Europe to demanding quality standards.
- Low endotoxin level ≤ 0.20 EU/mL.
- Intra-articular durability of up to 12 months.
- Optimal viscosity and elasticity that adapt to movement.
- Greater resistance to enzymatic degradation.
- Helps improve the patient's symptoms.
- Promotes recovery of joint function.
Indications
TrHCROSS 2.0% is indicated for viscosupplementation of knee-joint synovial fluid using cross-linked hyaluronic acid when synovial fluid viscosity has decreased due to osteoarthritis.
Properties
- Reduces pain and increases function in the affected joint.
- Provides lubricating and cushioning effects in the joint.
- Improves the patient's quality of life.
Directions for use
TrHCROSS 2.0% must be administered intra-articularly only by healthcare professionals specialising in traumatology.
The recommended dose of TrHCROSS 2.0% is 4.4 mL, administered as a single intra-articular injection.
Technology
SARE Technology®
An innovative hyaluronic acid cross-linking method that delivers unique results through a highly homogeneous cross-linking process.
A proprietary combination of low- and high-molecular-weight hyaluronic acid that creates a polymer matrix with a low degree of modification.
- Manufactured in Europe to demanding quality standards.
- Low endotoxin level ≤ 0.20 EU/mL.
- Intra-articular durability of up to 12 months.
- Optimal viscosity and elasticity that adapt to movement.
- Greater resistance to enzymatic degradation.
- Helps improve the patient's symptoms.
- Promotes recovery of joint function.
Productos relacionados
TrHCROSS 2.0 %
Formulated using SARE Technology to ensure improved joint function and longer-lasting results.
TrHCROSS mini 2.0 %
Intra-articular injection of cross-linked hyaluronic acid using SARE Technology for small joints.
TrHLINE 1.0 %
Restores the viscoelastic properties of synovial fluid, improving mobility and reducing joint friction in osteoarthritis.
TrHLINE 2.0 %
Restores the viscoelastic properties of synovial fluid, relieving pain and increasing mobility.
TrHPHYTO
Formulated through a rigorous scientific process with cannabidiol to provide comfort and well-being in localised areas.
TrHPLUS
Strengthens and protects the joints